A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Axonics, Inc. stock. As of the latest transaction made, Bridgewater Associates, LP holds 46,499 shares of AXNX stock, worth $3.12 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
46,499
Previous 54,156 14.14%
Holding current value
$3.12 Million
Previous $3.37 Million 4.84%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$56.67 - $69.36 $433,922 - $531,089
-7,657 Reduced 14.14%
46,499 $3.21 Million
Q4 2023

Feb 14, 2024

SELL
$49.38 - $63.75 $303,341 - $391,616
-6,143 Reduced 10.19%
54,156 $3.37 Million
Q3 2023

Nov 13, 2023

BUY
$48.64 - $62.51 $268,881 - $345,555
5,528 Added 10.09%
60,299 $3.38 Million
Q2 2023

Aug 11, 2023

SELL
$47.99 - $60.21 $277,094 - $347,652
-5,774 Reduced 9.54%
54,771 $2.76 Million
Q1 2023

May 12, 2023

BUY
$52.6 - $67.34 $137,864 - $176,498
2,621 Added 4.52%
60,545 $3.3 Million
Q4 2022

Feb 13, 2023

SELL
$59.56 - $76.6 $1.06 Million - $1.36 Million
-17,798 Reduced 23.5%
57,924 $3.62 Million
Q3 2022

Nov 10, 2022

BUY
$57.96 - $78.12 $726,528 - $979,234
12,535 Added 19.84%
75,722 $5.33 Million
Q2 2022

Aug 11, 2022

BUY
$39.5 - $64.42 $403,097 - $657,406
10,205 Added 19.26%
63,187 $3.58 Million
Q1 2022

May 13, 2022

BUY
$43.74 - $62.76 $568,707 - $816,005
13,002 Added 32.52%
52,982 $3.32 Million
Q4 2021

Feb 14, 2022

SELL
$50.01 - $73.35 $156,231 - $229,145
-3,124 Reduced 7.25%
39,980 $2.24 Million
Q3 2021

Nov 12, 2021

SELL
$59.21 - $78.66 $199,774 - $265,398
-3,374 Reduced 7.26%
43,104 $2.81 Million
Q2 2021

Aug 13, 2021

BUY
$51.39 - $66.9 $2.39 Million - $3.11 Million
46,478 New
46,478 $2.95 Million

Others Institutions Holding AXNX

About Axonics, Inc.


  • Ticker AXNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 49,123,600
  • Market Cap $3.3B
  • Description
  • Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention...
More about AXNX
Track Ray Dalio's Portfolio

Track Ray Dalio Portfolio

Follow Ray Dalio (Bridgewater Associates, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.